<DOC>
	<DOCNO>NCT02252731</DOCNO>
	<brief_summary>This study determine effect multiple dose FG-4592 pharmacokinetics ( PK ) single dose warfarin . It evaluate safety tolerability warfarin alone combination multiple dose FG-4592 , evaluate effect multiple dose FG-4592 pharmacodynamics ( PD ) warfarin .</brief_summary>
	<brief_title>A Study Evaluate Effects Multiple Doses FG-4592 Exposure , Safety Tolerability Effect Warfarin Healthy Subjects</brief_title>
	<detailed_description>The study consist 2 period , separate washout period ( minimum 14 day warfarin dose Day 1 , Period 1 ) . Screening take place Day -22 Day -2 . Subjects admit clinical unit Day -1 Period 1 . On Day 1 first period , subject receive single oral dose warfarin . After completion assessment Day 8 , subject discharge clinical unit condition medical reason prolong stay . They return clinical unit Day -1 second period , washout period . In Period 2 , subject receive multiple dos FG 4592 . On Day 7 Period 2 , FG 4592 give concomitantly warfarin . After completion assessment Day 16 Period 2 , subject discharge clinic condition medical reason prolong stay . The subject return End Study Visit ( ESV ) 5 9 day last assessment Period 2 ( early withdrawal ) . Safety assessment perform throughout study . Blood urine sample collect PK PD assessment .</detailed_description>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Male subject female spouse/partners childbearing potential must use highly effective contraception consist two form birth control . Male subject must donate sperm start screen throughout study period 90 day final study drug administration . Female subject must either nonchildbearing potential , childbearing potential , must negative pregnancy test screen Day 1 must use two form birth control . Female subject must donate ovum start screen throughout study period 28 day final study drug administration . Subject know suspected hypersensitivity FG 4592 , warfarin , component formulation use . Subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior admission clinical unit [ Day 1 ] . Subject lactose intolerant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Phase I</keyword>
	<keyword>FG-4592</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>